Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
about
Recent advances in the biology and drug targeting of malaria parasite aminoacyl-tRNA synthetasesEvolutionary Limitation and Opportunities for Developing tRNA Synthetase Inhibitors with 5-Binding-Mode ClassificationChinese Herbal Medicine-induced Liver InjuryAmino acid sensing in dietary-restriction-mediated longevity: roles of signal-transducing kinases GCN2 and TORATP-directed capture of bioactive herbal-based medicine on human tRNA synthetaseStructures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sicknessStructural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetaseA genomic and evolutionary approach reveals non-genetic drug resistance in malariaPlasmodium falciparum mitochondria import tRNAs along with an active phenylalanyl-tRNA synthetaseBiochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseHalofuginone Synergistically Enhances Anti-Proliferation of Rapamycin in T Cells and Reduces Cytotoxicity of Cyclosporine in Cultured Renal Tubular Epithelial CellsA dual-targeted aminoacyl-tRNA synthetase in Plasmodium falciparum charges cytosolic and apicoplast tRNACysStructural basis for full-spectrum inhibition of translational functions on a tRNA synthetaseConformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone.Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivationHalofuginone stimulates adaptive remodeling and preserves re-endothelialization in balloon-injured rat carotid arteriesNovel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.Indoleamine 2,3 dioxygenase and metabolic control of immune responses.Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice.Concise review: chemical approaches for modulating lineage-specific stem cells and progenitors.Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Novel and unique domains in aminoacyl-tRNA synthetases from human fungal pathogens Aspergillus niger, Candida albicans and Cryptococcus neoformans.Evolutionary molecular medicine.Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy.Structural Basis for Specific Inhibition of tRNA Synthetase by an ATP Competitive Inhibitor.Discovery of Dual-Stage Malaria Inhibitors with New Targets.Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases.The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity.The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.Therapeutic interventions to disrupt the protein synthetic machinery in melanomaAminoacyl-tRNA synthetases in medicine and diseaseTranslation Regulation of the Glutamyl-prolyl-tRNA Synthetase Gene EPRS through Bypass of Upstream Open Reading Frames with Noncanonical Initiation CodonsIdentifying the targets of aminoacyl-tRNA synthetase inhibitors by primer extension inhibition.Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase.Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.Simultaneous Pathway Activity Inference and Gene Expression Analysis Using RNA Sequencing.Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.Hypoxia and Mucosal Inflammation.
P2860
Q26749253-B93ADB91-2C49-42C2-9C67-D0F4DDE1FA42Q26775728-F8440512-A058-4591-BAB3-2FFC9DBE9DE5Q26781971-B52BCE3F-9E91-4708-9DC8-1F9EE3DDA3C8Q27001717-BD23DEB5-FAE9-4E1B-8C99-6D88BE59B4BBQ27675589-F0E406E5-5E16-467E-9BA0-55B8C82CAC02Q27683462-CA3587C2-9829-4AB3-94D9-B04E8BE6EE72Q27694602-1C8B7A3A-AEEA-4551-83EF-C4AF64A408B5Q27861944-DE0B04EB-7251-484A-A509-DA0EC5287D6AQ27974431-E4F39BE4-86EB-4432-A3E9-39785C6E864CQ28468285-0A3B469B-5789-41AE-8522-64F7F37F3509Q28551630-99CC64DC-701C-4DB7-B220-062F7B1CDF42Q30044413-EF1C4B10-A77A-4301-B731-6889CF7C8654Q30636920-CCEA0B9A-0AE0-4D39-9424-91EAEBFC3B4FQ32884591-A2FF270F-F82A-4E57-84F4-65E6E3506286Q34044497-D04F85C6-A85B-41B0-BF22-2DC328EF0C09Q34076223-EC32E990-A3EF-48D2-9E7C-B3232A73B1E0Q34285190-F4FCAF22-3810-416E-9977-8BAE660E458AQ34308495-A76BB3A6-4F2B-4950-9948-935116522A48Q34359125-3880D157-8945-4DD1-B0D9-4B93C531D345Q34666395-8F0DFA0B-4CA8-4B83-8FAB-3D590BD15A96Q35261125-BB10A3D2-6E4E-427D-AA29-02844EAC78CEQ35495212-D87CFBC3-F25B-4EB4-BABD-F97BC7E45D79Q35560450-E9039282-38EB-4515-9961-77179C7A42ADQ35592514-99E40C18-96FD-40AD-B51B-CE99507D28DDQ35691201-DF6A3F33-22F2-4C59-A50D-64B4DC686F74Q35854829-951A3B58-B603-4C67-92A5-B0923EEE36D3Q35868585-929526AA-39CF-42EA-BE66-53C1C2E837C1Q35952614-276A0C51-C8A6-41AA-95C9-DA10E94866F8Q36008229-6323903A-AC78-443B-8C31-53CE68314275Q36362906-D9C064CF-D133-4A7D-92B5-AFB2A68FD27DQ36473355-E2F7C956-7AE3-4E0A-8FCA-F7FA6CD98D3EQ36685930-0EE1BF9E-41A4-42BC-92B0-6ECD73A92400Q36898287-3DA2FB20-0577-4831-ACD0-47549B304159Q37080420-8D4DA4C6-49A6-412E-9857-2135B4899915Q37120074-4BC4FDC3-DD3D-41D7-8747-47D0A019D15EQ37235742-D3EF9B23-F08B-4EA3-866E-4B453B8B0FF5Q37274332-7A2F9A6A-7EC7-412C-820B-4BE21D4470E6Q37287878-0FC404B8-0138-41C0-8F15-94584AC00523Q37374550-1ECB8343-607B-4764-9AFB-462A296D0C52Q37550577-F0355EDD-98FD-4BBE-80B5-ED320759A16C
P2860
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@ast
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@en
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@nl
type
label
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@ast
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@en
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@nl
prefLabel
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@ast
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@en
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@nl
P2093
P2860
P50
P356
P1476
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
@en
P2093
Anjana Rao
Davide Zocco
Hak-Kyo Lee
John David Dignam
Joseph F Cortese
Maja Edenius
Malcolm Whitman
Margaret Hendrick
Mark S Sundrud
P2860
P2888
P304
P356
10.1038/NCHEMBIO.790
P577
2012-02-12T00:00:00Z